Search research articles
Contact Us
Filters
Showing results (451-460 of 465) with videos related to
Page
of 47
Sort By:
Cancer Discovery
|
June 15, 2013
Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers
Daniel Hagerstrand, Alexander Tong, Steven E Schumacher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2025
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.
Journal of Hematology & Oncology
|
April 26, 2026
Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2
Javier Muñoz, Frederick L Locke, Patrick M Reagan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2022
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study
Michael Wang, Javier Munoz, Andre Goy, et al.
Cold Spring Harbor Symposia on Quantitative Biology
|
September 2, 2004
Highly parallel SNP genotyping
J B Fan, A Oliphant, R Shen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2016
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
A Drilon, G Li, S Dogan, et al.
Bone Marrow Transplantation
|
January 4, 2024
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids
Olalekan O Oluwole, Edouard Forcade, Javier Muñoz, et al.
Cell
|
June 19, 2007
Integrative genomic approaches identify IKBKE as a breast cancer oncogene
Jesse S Boehm, Jean J Zhao, Jun Yao, et al.
Blood
|
October 29, 2025
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3
Tom van Meerten, Marie José Kersten, Gloria Iacoboni, et al.
Blood
|
February 23, 2023
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma
Sattva S Neelapu, Caron A Jacobson, Armin Ghobadi, et al.
Page
of 47
Search research articles
Search
Showing results (451-460 of 465) with videos related to
Sort By:
Page
of 47
Cancer Discovery
|
June 15, 2013
Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers
Daniel Hagerstrand, Alexander Tong, Steven E Schumacher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2025
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.
Journal of Hematology & Oncology
|
April 26, 2026
Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2
Javier Muñoz, Frederick L Locke, Patrick M Reagan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2022
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study
Michael Wang, Javier Munoz, Andre Goy, et al.
Cold Spring Harbor Symposia on Quantitative Biology
|
September 2, 2004
Highly parallel SNP genotyping
J B Fan, A Oliphant, R Shen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2016
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
A Drilon, G Li, S Dogan, et al.
Bone Marrow Transplantation
|
January 4, 2024
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids
Olalekan O Oluwole, Edouard Forcade, Javier Muñoz, et al.
Cell
|
June 19, 2007
Integrative genomic approaches identify IKBKE as a breast cancer oncogene
Jesse S Boehm, Jean J Zhao, Jun Yao, et al.
Blood
|
October 29, 2025
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3
Tom van Meerten, Marie José Kersten, Gloria Iacoboni, et al.
Blood
|
February 23, 2023
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma
Sattva S Neelapu, Caron A Jacobson, Armin Ghobadi, et al.
Page
of 47